Release Date: January 7, 2026
Expiration Date: January 7, 2027
Activity Overview
This online, on-demand virtual symposium brings together renowned experts in paroxysmal nocturnal hemoglobinuria (PNH). In this educational program, these experts engage in an in-depth exploration of PNH, with a focus on pathophysiology and disease burden, clinical manifestations, best practices for timely and accurate identification, and the evolving treatment landscape, including updates on current standards of care, novel complement inhibitors, and emerging therapeutic strategies.
This educational activity is an archive of the live symposium held on December 5, 2025.
Target Audience
This educational activity is directed toward hematologists, hematologist-oncologists, nurse practitioners, physician assistants, primary care physicians, and other clinicians involved in the management of patients with PNH.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Apply strategies to diagnose patients with PNH
- Identify pathophysiological processes that provide therapeutic targets for PNH
- Analyze clinical trial data for therapies for PNH
- Design individualized management plans for patients with PNH using shared decision-making principles
Caroline Piatek, MD
Associate Professor of Clinical Medicine
Jane Anne Nohl Division of Hematology
University of Southern California
Los Angeles, CA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Agios, Apellis, Argenx, AstraZeneca/Alexion, Janssen, Novartis, Omeros, Recordati, Regeneron, Rigel, Samsung Bioepis, Sanofi, Sobi; Grant/Research Funding: Alpine Immune Science, Argenx, AstraZeneca/Alexion, Eli Lilly, Incyte, Sanofi, Zenas BioPharma
Jamile M. Shammo, MD, FASCP, FACP
Dr Marjorie C. Barnett – Dr Hau C. Kwaan Endowed Chair
Professor of Medicine
Director, Bone Marrow Failure Program
Division of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alexion/AstraZeneca, Bristol Myers Squibb, GSK, Incyte, Novartis, Omeros, Regeneron, Sanofi, Sobi; Grant/Research Funding: Alexion, Incyte, Novartis; DSMB: Apellis
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here